Blog

Your blog category

May 13, 2026

Dark blue hero with large white title 'Bird in Hand vs Two in' and green subtitle; a four-panel color grid below: top-left gray 'Trader', top-right green 'COMPOUNDER', bottom-left light gray 'Drift', bottom-right orange 'Speculator'; small footer text on left reading 'Multibagger Shares' and page metadata on top right.

Bird in Hand vs Two in the Bush: Warren Buffett’s 2000 Berkshire Letter Reading of Aesop

Warren Buffett distilled Aesop into three questions every Indian investor must answer before laying out a single rupee — and Titan Biotech FY25 has audited answers to all three.

May 12, 2026

Hero section with Time Arbitrage title and italic subtitle; a 2x2 color grid: top-left Trader (gray), top-right COMPOUNDER (green), bottom-left Drift (light gray), bottom-right Speculator (orange).

Time Arbitrage: Why Stretching Your Holding Period to Five and Ten Years Is the Single Greatest Edge a Private Indian Investor Has Over Institutional Money

Why time arbitrage — the structural edge of holding quality businesses for five to ten years while institutional money is forced to optimise for the next 90 days — is the rarest source of edge in Indian value investing, illustrated by Titan Biotech's FY25 audited numbers.

May 11, 2026

Large page header with the title 'The Envy/Jealousy Tendency' and subtitle about Charlie Munger, set on a dark blue background; below is a 2x2 color grid labeled Lucky, Disciplined Investor, Confused, and Bias-Trapped.

The Envy/Jealousy Tendency: Charlie Munger’s 1995 Harvard Speech on Why It’s Not Greed That Drives the World

Charlie Munger's 1995 cognitive-bias #14 — the envy tendency — is the single cleanest explanation for India's ₹1.81 lakh crore F&O losses. Titan Biotech FY25's audited numbers read as a corporate version of the same discipline.

May 7, 2026

Chart: Opportunity Cost as Hurdle Rate by fiscal year FY20–FY25, with bars showing values 28, 26, 22, 18, 14 and a green FY25 bar at 11%.

Opportunity Cost as Hurdle Rate: Charlie Munger’s ‘Best Available Alternative’ Test

Charlie Munger's lifetime discipline: every rupee must beat the next-best alternative use, on a risk-adjusted basis. How Indian long-term investors apply the hurdle-rate test using the 10-year G-sec, and why Titan Biotech FY25's audited RoCE spread illustrates the discipline.

+91-8448836436